16 Sept 2025 • A meta-analysis of over 11.5 million individuals compared metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD).

MetALD was linked to higher risks of liver-related events (HR 1.62), hepatocellular carcinoma (HR 1.33), and extrahepatic cancers (HR 1.03) compared with MASLD, while risks of cardiovascular events, all-cause mortality, and extrahepatic cancer-related mortality were similar.

These results highlight distinct clinical profiles of MASLD and MetALD, emphasizing the need for tailored management and targeted therapies in steatotic liver disease.

Source: The Lancet | Read Full Story